FOLH1 and adenocarcinoma: CD46 is a new prostate cancer cell surface target that we identified and validated, which shows lineage independent homogeneous expression in both adenocarcinoma and small cell neuroendocrine mCRPC [15], differentiating from commonly targeted antigens such as PSMA.